NCT03752528 - Evaluation of Long-term Buprenorphine Plasma Exposure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 19, 2019

Primary Completion Date

July 18, 2019

Study Completion Date

July 18, 2019

Conditions

Opioid-use Disorder

Interventions

DIAGNOSTIC_TEST

Blood sample collection

Determination of buprenorphine and norbuprenorphine plasma concentrations

DIAGNOSTIC_TEST

Urine sample collection

Urine sample for determination of free buprenorphine and free norbuprenorphine concentrations, qualitative UDS for opioids, quantitative UDS for buprenorphine, norbuprenorphine and naloxone, and determination of creatinine concentration

Trial Locations (11)

16602

Clinical Research Associates of Central PA, LLC, Altoona

33606

Meridian Research, Tampa

35570

Pathway Healthcare, Hamilton

44720

Neurobehavioral Clinical Research, North Canton

66208

Phoenix Medical Research, Prairie Village

73112

Pahl Research, Oklahoma City

SP Research, Oklahoma City

75080

Pillar Research, Richardson

97232

CODA, Portland

02472

Adams Clinical, Watertown

08009

Hassman Research Institute, Berlin